Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activityIMC-I109V is a bispecific T cell receptor targeting ...

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders ...

About Vibrant Gastro Vibrant Gastro is a health‑tech company pioneering drug free therapeutics for gastrointestinal disorders ...

IES Holdings, Inc. (“IES”) (NASDAQ: IESC) and Gulf Island Fabrication, Inc. (“Gulf Island”) (NASDAQ: GIFI) today announced that they have entered into a definitive agreement, providing for the ...

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a ...

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidn ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).

Novanta has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,650,000 tangible equity units, solely to cover over-allotments, if any. Each tangible equity unit ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Blend Labs, Inc. (NYSE: BLND), a leading origination platform for digital banking solutions, today announced its third quarter 2025 financial results.

Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, ...